| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;95:1314-1319.)
© 1997 American Heart Association, Inc.
Articles |
Early Versus Delayed Angiotensin-Converting Enzyme Inhibition in Experimental Chronic Heart Failure
Effects on Survival, Hemodynamics, and Cardiovascular Remodeling
the Departments of Pharmacology (P.M., B.D., V.R., J.-P.H., M.-C.W., E.T., C.T.) and Histology (B.M.), VACOMED, IFRMP 23, Rouen University Medical School, Rouen, France.
Correspondence to C. Thuillez, MD, PhD, Service de Pharmacologie, CHU de Rouen, 76031 Rouen Cedex, France. E-mail Christian.Thuillez{at}chu-rouen.fr
Background The efficacy of ACE inhibitors in congestive heart failure (CHF) might be affected by the pathophysiological status present at the onset of treatment. We compared in a rat model the effects of ACE inhibition (lisinopril, 10 mg·kg-1·d-1) initiated early (1 week) or late (3 months) after myocardial infarction (ie, at time points corresponding to moderate or severe CHF without or with established cardiac remodeling).
Methods and Results Survival was improved by early treatment at 3 months (from 76% to 95%) and by both early and delayed treatment at 9 months (placebo, 28%; early, 90%; delayed, 61%). Delayed treatment was initiated in a more severe pathophysiological context of CHF than early treatment, illustrated in untreated rats by higher left ventricular (LV) end-diastolic and central venous pressures and by increased LV weight and LV cavity circumference. After 9 months, early and delayed treatments reduced systolic, LV end-diastolic, and central venous pressures. Both treatments also similarly decreased LV weight, LV cavity circumference, and LV collagen density.
Conclusions In this rat model of CHF, early and delayed ACE inhibitor treatments both increase survival and exert similar beneficial effects on cardiac hemodynamics and remodeling. Although early treatment prevents the development of ventricular dysfunction and remodeling, delayed treatment is capable of reversing cardiac hypertrophy and remodeling, as well as ventricular dysfunction. Thus, ACE inhibitors exert marked beneficial effects even when treatment is initiated late into the evolution of heart failure (ie, at a time of established ventricular dysfunction and remodeling).
Key Words: angiotensin • heart failure • hypertrophy • pharmacology
This article has been cited by other articles:
 |
|
 |
|
  A. R. Kompa, F. See, D. A. Lewis, A. Adrahtas, D. M. Cantwell, B. H. Wang, and H. Krum Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 741 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mellin, M. Isabelle, A. Oudot, C. Vergely-Vandriesse, C. Monteil, B. Di Meglio, J. P. Henry, B. Dautreaux, L. Rochette, C. Thuillez, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure Eur. Heart J., August 1, 2005; 26(15): 1544 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulder, S. Barbier, A. Chagraoui, V. Richard, J. P. Henry, F. Lallemand, S. Renet, G. Lerebours, F. Mahlberg-Gaudin, and C. Thuillez Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure Circulation, April 6, 2004; 109(13): 1674 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chen, C. X. Chen, X. T. Gan, N. Beier, W. Scholz, and M. Karmazyn Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H381 - H387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Agata, L. Chao, and J. Chao Kallikrein Gene Delivery Improves Cardiac Reserve and Attenuates Remodeling After Myocardial Infarction Hypertension, November 1, 2002; 40(5): 653 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nomoto, T. Nishina, S. Miwa, H. Tsuneyoshi, I. Maruyama, K. Nishimura, and M. Komeda Angiotensin-Converting Enzyme Inhibitor Helps Prevent Late Remodeling After Left Ventricular Aneurysm Repair in Rats Circulation, September 24, 2002; 106(12_suppl_1): I-115 - I-119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, H. Boujedaini, V. Richard, J.-P. Henry, S. Renet, K. Munter, and C. Thuillez Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure: Monotherapy Versus Combination Therapy Circulation, August 27, 2002; 106(9): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-G. Xia, O. Chung, H. Spitznagel, S. Illner, G. Janichen, B. Rossius, P. Gohlke, and T. Unger Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure Cardiovasc Res, January 1, 2001; 49(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A.M. Zornoff, S. A.R. Paiva, B. B. Matsubara, L. S. Matsubara, and J. Spadaro Combination Therapy with Angiotensin Converting Enzyme Inhibition and AT1 Receptor Inhibitor on Ventricular Remodeling After Myocardial Infarction in Rats Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 203 - 209. [Abstract] [PDF]
|
|
|
|
|
|
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer Interactions among ACE, kinins and NO Cardiovasc Res, August 15, 1999; 43(3): 549 - 561. [Full Text] [PDF]
|
|
|
|
|
|
M. Ruzicka, B. Yuan, and F. H. H. Leenen Blockade of AT1 receptors and Na+/H+ exchanger and LV dysfunction after myocardial infarction in rats Am J Physiol Heart Circ Physiol, August 1, 1999; 277(2): H610 - H616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bastien, A.-V. Juneau, J. Ouellette, and C. Lambert Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival Cardiovasc Res, July 1, 1999; 43(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Varin, P. Mulder, V. Richard, F. Tamion, C. Devaux, J.-P. Henry, F. Lallemand, G. Lerebours, and C. Thuillez Exercise Improves Flow-Mediated Vasodilatation of Skeletal Muscle Arteries in Rats With Chronic Heart Failure : Role of Nitric Oxide, Prostanoids, and Oxidant Stress Circulation, June 8, 1999; 99(22): 2951 - 2957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bibevski and M. E. Dunlap Ganglionic Mechanisms Contribute to Diminished Vagal Control in Heart Failure Circulation, June 8, 1999; 99(22): 2958 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Richer, P. Fornes, C. Cazaubon, V. Domergue, D. Nisato, and J.-F. Giudicelli Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats Cardiovasc Res, January 1, 1999; 41(1): 100 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Richard, F. Bouchart, G. Derumeaux, K. Munter, and C. Thuillez Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure Cardiovasc Res, September 1, 1998; 39(3): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Richard, G. Derumeaux, M. Hogie, J. P. Henry, F. Lallemand, P. Compagnon, B. Mace, E. Comoy, B. Letac, et al. Role of Endogenous Endothelin in Chronic Heart Failure : Effect of Long-term Treatment With an Endothelin Antagonist on Survival, Hemodynamics, and Cardiac Remodeling Circulation, September 16, 1997; 96(6): 1976 - 1982. [Abstract] [Full Text]
|
|